About HLK
Management Members


Ms. Jun Xu,  President (Founder)

15 years of experience in drug discovery and development in multi-national pharmaceutical companies (Novartis,Boehringer Ingelheim)

 Responsible for various discovery and development projects

          Resposible for operation and business development ; US pharma business with Chinese pharma companies

 




Dr. Zeren Wang,  CSO (Founder)

 Zeren received his PhD in Physical Pharmacy from University of Utah, Dr. William Higuchi’s lab. He is responsible for the  overall science and technical management of the company. Prior to this position, Zeren was the Director of Formulation Development, at Boehringer Ingelheim Pharmaceuticals Inc, Ridgefield, CT. In this role, he provided strategic leadership to a team focused on formulation and process  development of NCE products. Zeren is specialized in formulation development of poorly water soluble compounds for oral delivery and experienced in the development of oral solid dosage forms (tablets, hard gelatin capsules, soft gelatin capsules), oral liquid dosage forms (solutions and suspensions), controlled release technology, and parenterals (lyophilization). Under his leadership, his team introduced and implemented multiple new formulation technologies including SEDDS (self emulsifying drug delivery system) formulation technologies (soft gel and hard gel encapsulation capabilities), solid dispersion formulation technologies (spray drying and melt extrusion) as well as nano-milling. He has 30 peerreviewed publications and patents, as well as numerous poster presentations. 

 


 


Dr. Peter Farina,  Chairman of SAB

Dr. Peter Farina is an Executive in Residence at Canaan Partners, a venture capital firm, located in Westport, CT where he assesses and advises on pharma/biotech/healthcare investments. He is also the managing partner of a consulting firm, Salient Science & Technology, LLC which advises several biotech firms on strategic and technical matters in pharmaceutical R&D. Dr. Farina currently serves as the Co-Chair and Board Member of Connecticut United for Research Excellence (CURE); the Advisory Board of the University of Connecticut School of Pharmacy, member of the NIH Blueprint Neurotherapeutics Network (BPN) steering committee; Emory University DRIVE Advisory Board, and was a Founder and CEO of Developing World Cures, a nonprofit company working on neglected diseases.

Dr. Peter Farina retired in 2008 as Senior Vice President of Development at Boehringer Ingelheim Pharmaceuticals, Inc. in Ridgefield, CT where he was responsible for North American development of drugs in the therapeutics areas of Immunology/Inflammation, Virology and Cardiovascular Disease. During his tenure as SVP at BI, his interdisciplinary team worked on the development and successful registration of Aptivus, an HIV protease inhibitor, Viramune XR for HIV and Atrovent HFA for COPD and emphysema. Prior to this position he served as Vice President of Research at the Ridgefield Center. He has also held positions as Director of Inflammatory Diseases and Director of Biochemistry over his 28 year career with Boehringer Ingelheim. Prior to joining BI he spent 6 years in the Corporate Research Laboratories and Medical Products Division of Union Carbide Corporation in Tarrytown, NY where he did research and development of immunodiagnostics. Dr. Farina’s research interest has been generally at the interface of chemistry and biology. He is the author of over fifty publications and patents.

 


 


Dr. Yijun Cheng

 Oncologist, Buffalo Medical Group 


          Cancer biology PhD at the University of Texas MD Anderson Cancer Center 


          Board certified in Internal Medicine, Oncology and Hematology, Member of American College of 


          Physicians, American Society of Clinical Oncology, American Society of Hematology


          Broad experience in clinical research


                                        Consultant of multiple multinational pharmaceutical companies





 


Stan Choy,  COO of HLK Pharmacin in the US

Stan is a senior executive and business leader with over 25 years of healthcare, biotechnology and professional services experience.  Prior to his start-up company experiences, Stan was the Chief Financial Officer for a leading Am Law 100 law firm, Edwards Angell, Palmer & Dodge LLP.  From 2003-2006, Stan served as Financial Controller with Shearman & Sterling LLP.  Prior to joining the legal industry, Stan spent eleven years at Pfizer Inc., and held several senior financial management position.  He started his career with Arthur Andersen & Co; working in the audit and tax practices. 


He is a seasoned and experienced business leader with extensive hands on management expertise including financial and strategic planning, and global business development. CFO with 25 years operational and finance experience with a Fortune 50 premier healthcare and global professional services organizations.  Experienced in negotiating and consulting with government authorities, regulatory agencies, investment community and external auditors.  Managed and developed a large global finance organization. Stan has an MBA from Syracuse University and is a Certified Public Accountant.  He is a member of the American Institute of CPA’s, and NYS Society of CPA’s.  Currently, he Co-Chairs and board member of BioCT, the biotechnology industry trade representive for Connecticut.


Tel: +86-755-86007001   Email: info@hlkpharma.com